mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
By Nanxin Li, Boyoung Lee, Rong‐jian Liu, M. Banasr, J. Dwyer, M. Iwata, Xiao-Yuan Li, G. Aghajanian, R. Duman. Science, 2010
2,783 citations recorded by the source corpus.
Antidepressant Action of Ketamine In contrast to the weeks or months of treatment required for standard antidepressant medication, ketamine administration produces an antidepressant response within 4 to 6 hours in depressed patients. What lies behind the rapid actions of ketamine? Li et al. (p. 959; see the Perspective by Cryan and O'Leary) found that ketamine administration resulted in fast activation of mammalian target of rapamycin (mTOR) signaling and increased levels of synaptic proteins in the rat prefrontal cortex. Ketamine rapidly increased the density and function of the dendritic spines of layer V pyramidal neurons in the prefrontal cortex. Thus, the behavioral actions of ketamine in models of depression and antidepressant response are dependent on mTOR signaling. Ketamine, an anaesthetic and recreational drug, rapidly increases synaptic signaling and antidepressant behavioral responses. The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for standard medications. However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-d-aspartic acid (NMDA) receptor antagonist] have not been identified. We observed that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats. Moreover, blockade of mTOR signaling completely blocked ketamine induction of synaptogenesis and behavioral responses in models of depression. Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine.
Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Pharmacology
View Paper: https://www.semanticscholar.org/paper/dc57b737e18ec3125218486db05a26fe1c5988f2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biological Psychiatry
In Cellular and Molecular Neuroscience
- R. Duman
- L. Monteggia
- G. Sanacora
- Anita E. Autry
- Dennis S. Charney
- P. Willner
- Andrew H. Miller
- C. Björkholm
In Pharmacology
- L. Monteggia
- R. Duman
- Anita E. Autry
- G. Sanacora
- S. Mathew
- P. Willner
- David M. Sabatini
- R. A. Saxton
Citations in the corpus
- Towards a glutamate hypothesis of depression (2011, background): “…sustained effects in rodent models similar to those seen in depressed patients (Autry et al., 2011; Du et al., 2006; Koike et al., 2011; Li et al., 2010, 2011; Maeng et al., 2008; Yilmaz et al., 2002), others have failed to demonstrate the enduring effects of an acute ketamine dosing…”
- Psychedelics Promote Structural and Functional Neural Plasticity (2018, methodology): “We specifically designed these experiments to mimic previous studies of ketamine (Li et al., 2010) so that we might directly compare these two compounds, and, to a first approximation, they appear to be remarkably similar.”
- The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain (2017, background): “Furthermore, by antagonizing the glutamatergic NMDA receptor, ketamine was found to accelerate the release of presynaptic glutamate, thereby enhancing the regional activity of the excitatory network, and eventually leading to a significant change in synaptic plasticity and connectivity [108, 109].”
- mTOR Signaling in Growth, Metabolism, and Disease. (2017, background): “Consistent with this, the NMDA receptor antagonist ketamine acutely activates mTORC1 signaling in mouse neurons, which coincides with an increased translation of synaptic proteins (Li et al., 2010).”
- Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “One study found decreased T reg percentage in association with reduced IL-10 and TGF-beta in depressed patients versus controls (Li et al., 2010b), and a second study reported that antidepressant treatment led to increased CD4+CD25+ T reg percentage, which was associated with decreased IL-1-beta…”
- Glutamate NMDA receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure (2011, positive): “The requirement for mTOR signaling is consistent with our recent findings that ketamine directly activates several components of the mTOR pathway (25).”
- mTOR Signaling in Growth, Metabolism, and Disease (2017, background): “Consistent with this, the NMDA receptor antagonist ketamine acutely activates mTORC1 signaling in mouse neurons, which coincides with an increased translation of synaptic proteins (Li et al., 2010).”
- NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses (2011, background): “Recent evidence indicates that cortical mTOR signalling underlies ketamine-mediated antidepressant response”
- Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression (2012, positive): “While the riluzole for relapse prevention strategy was based on potential synergy between ketamine and riluzole involving modulation of glutamate signaling, the recent identification of additional signaling pathways implicated in the antidepressant action of ketamine suggests new targets for synergy”